Literature DB >> 14724433

Donor hypertension increases graft immunogenicity and intensifies chronic changes in long-surviving renal allografts.

Johann Pratschke1, Dustin Paz, Markus J Wilhelm, Igor Laskowski, Gregorz Kofla, Athanasios Vergopoulos, Harald J MacKenzie, Stefan G Tullius, Peter Neuhaus, Wayne W Hancock, Hans-Dieter Volk, Nicholas L Tilney.   

Abstract

BACKGROUND: Marginal donor organs are used increasingly for transplantation. To define the influences of donor hypertension, we compared the behavior of kidney allografts from hypertensive and normotensive donors in an established rat model of chronic rejection.
METHODS: Donor hypertension was induced by partial occlusion of the right renal artery with a silver clip. After 10 weeks, the left kidney was removed and transplanted. Normotensive animals served as controls. All recipients were treated with a low dose of cyclosporine for 10 days (1.5 mg/kg). Blood pressure and proteinuria were determined weekly four times after transplantation. To examine the effects of donor hypertension on late events, grafts (n=6/time point) were examined morphologically and by quantitative reverse transcriptase-polymerase chain reaction analysis at serial intervals.
RESULTS: Recipients of kidneys from hypertensive donors developed systemic hypertension in contrast with normotensive controls (P<0.05). Allografts from hypertensive animals showed accelerated deterioration in structure and function after transplantation. Proteinuria became significantly elevated as early as 6 weeks (P<0.05) compared with controls and increased progressively thereafter (P<0.005). Grafts from hypertensive donors, histologically normal at the time of engraftment, developed significant morphologic deterioration after 12 weeks (P<0.01). Changes in allografts from normotensive donors remained minor. mRNA of proinflammatory mediators in hypertensive donor grafts (P<0.01) was up-regulated before transplantation and increased progressively over time (P<0.01).
CONCLUSIONS: Donor hypertension intensifies the chronic injury associated with allogeneic kidney transplantation in the rat model used. This condition also leads to induction of recipient hypertension and may be a more important risk factor for chronic graft dysfunction than previously appreciated.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14724433     DOI: 10.1097/01.TP.0000092003.02115.95

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  5 in total

1.  Organ donations and unused potential donations in traumatic brain injury, subarachnoid haemorrhage and intracerebral haemorrhage.

Authors:  Erwin J O Kompanje; Jan Bakker; François J A Slieker; Jan N M IJzermans; Andrew I R Maas
Journal:  Intensive Care Med       Date:  2006-01-24       Impact factor: 17.440

2.  Dominant predictors of early post-transplant outcomes based on the Korean Organ Transplantation Registry (KOTRY).

Authors:  Jong Cheol Jeong; Tai Yeon Koo; Han Ro; Dong Ryeol Lee; Dong Won Lee; Jieun Oh; Jayoun Kim; Dong-Wan Chae; Young Hoon Kim; Kyu Ha Huh; Jae Berm Park; Yeong Hoon Kim; Seungyeup Han; Soo Jin Na Choi; Sik Lee; Sang-Il Min; Jongwon Ha; Myoung Soo Kim; Curie Ahn; Jaeseok Yang
Journal:  Sci Rep       Date:  2022-05-24       Impact factor: 4.996

3.  Low-dose carbon monoxide inhibits progressive chronic allograft nephropathy and restores renal allograft function.

Authors:  Atsunori Nakao; Gaetano Faleo; Michael A Nalesnik; Joao Seda-Neto; Junichi Kohmoto; Noriko Murase
Journal:  Am J Physiol Renal Physiol       Date:  2009-04-15

Review 4.  The mononuclear phagocyte system in homeostasis and disease: a role for heme oxygenase-1.

Authors:  Travis D Hull; Anupam Agarwal; James F George
Journal:  Antioxid Redox Signal       Date:  2014-03-03       Impact factor: 8.401

5.  Receiving Hypertensive Donor Grafts Is Associated with Inferior Prognosis in Simultaneous Liver-Kidney Transplantation Recipients.

Authors:  Zebin Zhu; Shanzhou Huang; Qiang Zhao; Yunhua Tang; Zhiheng Zhang; Linhe Wang; Weiqiang Ju; Zhiyong Guo; Xiaoshun He
Journal:  Med Sci Monit       Date:  2018-04-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.